Cognoptix is a developer of non-invasive eye scanning tests for early detection of Alzheimer's Disease. The company is developing technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye, to examine and measure deposits in specific areas of the lens as a means of early detection of Alzheimer’s disease. Their SAPPHIRE eye test uses Fluorescent Ligand Scanning (FLS) is a technique in which a compound composed of beta amyloid-specific small molecules is dropped Founded in 2001, headquartered in Acton, United States. The company has raised $41.3M at the Series D stage backed by investors including Inventages, Alopexx, Launchpad Venture Group, Maine Angels, Quan Funds. Operating in High Tech > Eye Tracking, Life Sciences > Neurology.
Cognoptix
Series DCognoptix is a developer of non-invasive eye scanning tests for early detection of Alzheimer's Disease. The company is developing technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye, to examine and measure deposits in specific areas of the lens as a means of early detection of Alzheimer’s disease. Their SAPPHIRE eye test uses Fluorescent Ligand Scanning (FLS) is a technique…
About
Business model
Eye Tracking > Applications > Healthcare,
Healthcare IT > Provider > Clinical Operations > Decision Support > Diagnosis > Diagnostics and Assessment Tests > Cognitive Assesment > Eye tracking,
Neurology > Medical Devices > Screening Devices
Institutional investors
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Backed by funds in our directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.